Form 4 Tracker
Dianthus Therapeutics, Inc. /DE/
DNTH

32 insider filings · Latest: Sep 17, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Jun 1, 2026Jun 2 11:00 PMSimrat RandhawaEVP, Head of R&D
Sale
26,530$90.62$2.4M4,000(D)

View →

Jun 1, 2026Jun 1 8:13 PMSIMRAT RANDHAWA
Proposed Sale
26,530$93.01$2.5M—

View →

May 8, 2026May 11 9:00 PMPaula SoteropoulosDirector
Sale
599$85.47$51.2K0(D)

View →

Apr 9, 2026Apr 10 8:52 PMRyan SavitzEVP, CFO & CBO
Sale
8,224$89.84$738.8K0(D)

View →

Apr 9, 2026Apr 9 8:22 PMRYAN SAVITZ
Proposed Sale
8,224$87.48$719.4K—

View →

Mar 31, 2026Apr 1 9:26 PMRyan SavitzEVP, CFO & CBO
Sale
114,367$83.00$9.5M0(D)

View →

Mar 31, 2026Apr 1 9:26 PMPaula SoteropoulosDirector
Sale
599$80.11$48.0K0(D)

View →

Mar 31, 2026Mar 31 8:25 PMRYAN SAVITZ
Proposed Sale
114,367$79.45$9.1M—

View →

Mar 31, 2026Mar 31 8:21 PMPAULA C SOTEROPOULOS
Proposed Sale
1,198$79.45$95.2K—

View →

Mar 24, 2026Mar 26 10:00 PMPaula SoteropoulosDirector
Sale
27,594$78.05$2.2M0(D)

View →

Mar 24, 2026Mar 24 8:29 PMPAULA C SOTEROPOULOS
Proposed Sale
27,594$79.32$2.2M—

View →

Mar 12, 2026Mar 14 12:30 AMMarino GarciaDirector, CEO AND PRESIDENT
Sale
122,918$81.49$10.0M0(D)

View →

Mar 12, 2026Mar 14 12:30 AMEdward CarrCHIEF ACCOUNTING OFFICER
Sale
43,682$81.49$3.6M0(D)

View →

Mar 12, 2026Mar 14 12:30 AMSimrat RandhawaEVP, Head of R&D
Sale
33,830$81.48$2.8M0(D)

View →

Mar 12, 2026Mar 12 8:59 PMMARINO GARCIA
Proposed Sale
122,918$85.84$10.6M—

View →

Mar 12, 2026Mar 12 8:30 PMSIMRAT RANDHAWA
Proposed Sale
33,830$85.84$2.9M—

View →

Mar 12, 2026Mar 12 8:23 PMEDWARD CARR
Proposed Sale
43,682$85.84$3.7M—

View →

Dec 4, 2025Dec 4 9:42 PMRYAN SAVITZ
Proposed Sale
20,000$43.97$879.4K—

View →

Nov 13, 2025Nov 13 9:23 PMSIMRAT RANDHAWA
Proposed Sale
196,538$38.72$7.6M—

View →

Sep 9, 2025Sep 9 8:27 PMRYAN SAVITZ
Proposed Sale
20,000$31.80$636.0K—

View →

← Previous

Page 2 of 2

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Apr 9, 2026Apr 10 8:52 PMRyan SavitzEVP, CFO & CBO
Option Exercise
8,224$17.8871,776(D)

View →

Mar 31, 2026Apr 1 9:26 PMRyan SavitzEVP, CFO & CBO
Option Exercise
114,367$17.8880,000(D)

View →

Mar 31, 2026Apr 1 9:26 PMPaula SoteropoulosDirector
Option Exercise
599$8.44599(D)

View →

Mar 24, 2026Mar 26 10:00 PMPaula SoteropoulosDirector
Option Exercise
27,594$8.441,198(D)

View →

Mar 16, 2026Mar 17 9:22 PMMarino GarciaDirector, CEO AND PRESIDENT
Option Exercise
65,292$17.88269,408(D)

View →

Mar 12, 2026Mar 14 12:30 AMMarino GarciaDirector, CEO AND PRESIDENT
Option Exercise
122,918$6.7059,741(D)

View →

Mar 12, 2026Mar 14 12:30 AMEdward CarrCHIEF ACCOUNTING OFFICER
Option Exercise
43,682$22.0750,000(D)

View →

Mar 12, 2026Mar 14 12:30 AMSimrat RandhawaEVP, Head of R&D
Option Exercise
33,830$22.07106,250(D)

View →

Feb 3, 2026Feb 4 10:42 PMEdward CarrCHIEF ACCOUNTING OFFICER
Grant/Award
55,000$52.4655,000(D)

View →

Feb 3, 2026Feb 4 10:41 PMAdam M VenessSVP, General Counsel and Sec.
Grant/Award
100,000$52.46100,000(D)

View →

Feb 3, 2026Feb 4 10:40 PMSimrat RandhawaEVP, Head of R&D
Grant/Award
150,000$52.46150,000(D)

View →

Feb 3, 2026Feb 4 10:40 PMRyan SavitzEVP, CFO & CBO
Grant/Award
150,000$52.46150,000(D)

View →

Feb 3, 2026Feb 4 10:39 PMMarino GarciaDirector, CEO AND PRESIDENT
Grant/Award
355,000$52.46355,000(D)

View →

← Previous

Page 2 of 2